PLASMONIC BEADS FOR MULTIPLEXED ANALYSIS BY FLOW DETECTION SYSTEMS

• US 20160216252A1
• Filed: 09/11/2014
• Published: 07/28/2016
• Est. Priority Date: 09/13/2013
• Status: Abandoned Application

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford University)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford University)
• Inventors: Zou, Yingping, Yang, Jiang, Zhang, Bo, Dai, Hongjie, Gong, Ming
• Application Number:
  US14/917,525
• Publication Number:
  US 20160216252A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G01N 33/533 with fluorescent label
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching
• CPC Class Codes: G01N 33/54373 involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
• CPC Class Codes: G01N 33/553 Metal or metal coated

Abstract

Disclosed are methods and assays for detection of low concentration analytes such as proteins in a sample, using beads. Specially coated beads allow for femtomolar sensitivity through strong near-infrared fluorescence enhancement on plasmonic beads having gold nanostructures in a coating. By selecting different bead sizes and labeling with different fluorophores of plasmonic beads for immobilization of different capture antibodies, multiplexed plasmonic beads can be used for simultaneous quantification of various markers down to 0.01 pg/mL sensitivity. Exemplified are human cytokine IL-6, IFN-gamma, IL-1 beta, VEGF and ovarian cancer biomarker CA-125. Using flow cytometry, a detection limit below that of glass bead based immunoassays by 2-3 orders of magnitude was achieved. The multiplexed plasmonic bead assay was used to simultaneously quantify cytokines and CA125 of ovarian cancer cell culture medium, demonstrating the potential of plasmonic bead based immunoassay for sensitive biological detection relevant to human diseases.

Claims

1. A method for detection of analytes in a sample, comprising:

(a) contacting the sample with a population of microparticles in suspension, said microparticles comprising a plasmonically active surface providing near-infrared (“

NIR”

) enhanced fluorescence, said fluorescence optionally provided by gold nano-island covering a portion of said microparticles, said population of microparticles further comprising subpopulations comprising different analyte capture molecules bound to said plasmonically active surface;

(b) allowing said different analyte capture molecules to form complexes with different analytes that may be present in the sample;

(c) labeling complexes formed in step (b) with fluorescent labels;

(d) detecting labeled complexes by irradiating said fluorescent labels and sensing metal enhanced fluorescence from labeled complexes, whereby NIR enhanced fluorescence from said microparticles indicates detection of analytes; and

(e) distinguishing multiple analytes in the sample, if present, by different NIR enhanced fluorescence signals.

2. The method of claim 1 wherein the step of distinguishing multiple analytes is carried out and comprises use of at least one of

(i) different fluorescent labels attached to different captured analytes;

(ii) different microparticle sizes used to detect different analytes; and

(iii) different labels affixed to different microparticles used to detect different analytes.

3. The method of claim 2 wherein the step of distinguishing multiple analytes in the sample comprises measuring said different enhanced NIR fluorescent signals by flow cytometry.

4. The method of claim 1 wherein said subpopulations comprising different analyte capture molecules comprise different sized beads.

5. The method of claim 1 wherein the fluorescent labels are NIR dyes having emissions in the range of 650-800 nm.

6. The method of claim 1 wherein the plasmonically active surface comprises gold nano-islands.

7. The method of claim 6 wherein the plasmonically active surface comprises gold nano-islands coated on beads, said beads further selected from the group consisting of amine-functionalized silica-based, polymer-based and magnetic beads.

8. The method of claim 7 wherein said microparticles comprise an avidin layer on top of the plasmonically active surface.

9. The method of claim 6 wherein said analyte capture molecules are selected from the group consisting of antibodies, antigens, nucleic acids, carbohydrates, and binding peptides.

10. The method of claim 9 wherein said analyte capture molecules are biotinylated antibodies bound to an avidin layer on said microparticles.

11. The method of claim 5 wherein the steps of labeling complexes comprise steps of providing said analyte capture molecules selected from the group consisting of antibodies, antigens, DNA, and peptides, wherein said capture molecules are immobilized on surfaces of microparticles;

and providing a fluorescent label in the form of fluorescently labeled antibodies specific to said analytes, whereby a complex is formed between capture molecules, analyte, and fluorescently labeled antibodies or streptavidin.

12. The method of claim 1, wherein the step of distinguishing multiple analytes is done with antibodies having different specificities and labeled with different NIR labels having non-overlapping emission spectra.

29. The method of claim 2, wherein the fluorescent labels are NIR dyes having emissions in the range of 650-800 nm.

30. The method of claim 3, wherein the fluorescent labels are NIR dyes having emissions in the range of 650-800 nm.

31. The method of claim 2, wherein the plasmonically active surface comprises gold nano-islands.

32. The method of claim 2, wherein the step of distinguishing multiple analytes is carried out with antibodies having different specificities and labeled with different NIR labels having non-overlapping emission spectra.

33. The method of claim 3, wherein the plasmonically active surface comprises gold nano-islands.

34. The method of claim 3, wherein the step of distinguishing multiple analytes is carried out with antibodies having different specificities and labeled with different NIR labels having non-overlapping emission spectra.

35. The method of claim 4, wherein the step of distinguishing multiple analytes is carried out with antibodies having different specificities and labeled with different NIR labels having non-overlapping emission spectra.

13. A product comprising a population of beads wherein each bead comprises, on an outer surface thereof, gold islands separated by gaps of between 5 and 100 nm, and said gold islands have an area between either 1,000 and 2,500 nm², or 25 and 250,000 nm², said population of beads further having coupled thereto analyte capture molecules of at least two different specificities.

14. The product of claim 13 wherein said population of beads comprises at least two different sizes of beads.

15. The product of claim 13 wherein said population of beads comprises beads of silica-based, polymer-based, or magnetic material.

16. The product of claim 13 wherein said population of beads comprises beads of silica-based material modified with an amine functionality coupled to a plasmonically active layer.

17. The product of claim 13 wherein said population of beads comprises beads that are of sizes that differ by at least a factor of 1.5.

18. The product of claim 13 wherein said beads comprise different fluorescent labels.

19. The product of claim 13 wherein said population of beads comprises beads having outer surface gold islands of different sizes as between beads.

20. The product of claim 13 wherein said analyte capture molecules are antibody molecules of at least two different specificities.

21. The product of claim 13 wherein said analyte capture molecules are selected from the group consisting of antibodies, antigens, carbohydrates, nucleic acids and binding peptides.

22. A method of using an immunoassay product as defined in claim 13, comprising the steps of:

(a) forming a mixture of a sample with said population of beads;

(b) allowing capture molecules to bind to analytes in said sample;

(c) separating beads with bound analytes;

(d) forming a complex of bound analytes and fluorescently labeled detection molecules; and

(e) detecting the complex of step (d) by fluorescence, on a bead-by-bead basis, wherein said fluorescence is enhanced NIR fluorescence resulting from interaction between fluorescent labels on the fluorescently labeled detection molecules and the plasmonically active layer.

23. The immunoassay product of claim 22 wherein said detecting bead-by-bead is done by flow cytometry.

24. The immunoassay product of claim 22 wherein said detecting bead-by-bead is done by microscope imaging.

25. The immunoassay product of claim 23 wherein said flow cytometry distinguishes between different analytes by measuring both scattering and fluorescent emission peaks at different wavelengths.

26. The immunoassay product of claim 22 wherein the analyte is an antibody of a human or other species.

27. The immunoassay product of claim 22 wherein the fluorescently labeled detection molecules are antibodies that are labeled with an NIR dye.

36. The product of claim 13, wherein said population of beads comprises between three and five different sizes of beads.

28. A method of making a bead-based immunoassay product comprising a population of beads, comprising the steps of:

(a) modifying beads having a material that is one of a silica-based, polymer-based, or magnetic material with an amine functionality

(b) coupling the beads to a plasmonically active layer comprising gold islands separated by gaps of 5 and 100 nm and wherein the islands are between 1,000 and 2,500 nm², or between 25 and 250,000 nm², in area;

(c) applying to the beads a functionality for coupling thereto a population of detection molecules; and

(d) coupling detection molecules of different specificities to the beads as prepared in steps (a)-(c).